NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness
  • Phase

    Phase 4
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    natalizumab ...
  • Study Participants

The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving Natalizumab for 6 months relative to baseline.
Natalizumab has been shown to positively impact fatigue and cognition. The mechanism by which this occurs is unknown. Change in quality of sleep is one possible etiology of these findings. This study will help to elucidate the mechanisms that lead to reduced fatigue/sleepiness and less cognitive dysfunction in MS patients who go on Natalizumab therapy. Understanding these factors may help neurologists better differentiate between the different therapeutic options for MS and how they may impact symptoms that negatively affect quality of life.
Study Started
Mar 31
Primary Completion
Aug 31
Study Completion
Aug 31
Last Update
Jan 29

Drug Natalizumab (Tysabri)

300 mg IV every 4 weeks

Natalizumab (Tysabri) naive Other

Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.


Inclusion Criteria:

Relapsing form of multiple sclerosis
Able to give informed consent and committed to follow the protocol
EDSS from 0 to 6.0
Epworth Sleepiness Scale > 9 or Modified Fatigue Impact Scale > 30 or Fatigue Severity Scale > 4
Age range of 18 - 65 years of age
Naïve to Natalizumab
Enrolled in the TOUCH program

Exclusion Criteria:

Severe cognitive impairment
Coexisting severe medical condition
Inability to speak English or read
Inability to give valid informed consent.
No Results Posted